[1]
Alm A. Latanoprost in the treatment of glaucoma. Clinical ophthalmology (Auckland, N.Z.). 2014:8():1967-85. doi: 10.2147/OPTH.S59162. Epub 2014 Sep 26
[PubMed PMID: 25328381]
[2]
Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert opinion on pharmacotherapy. 2012 Apr:13(5):723-45. doi: 10.1517/14656566.2012.662219. Epub 2012 Feb 21
[PubMed PMID: 22348427]
Level 3 (low-level) evidence
[3]
Radell JE, Serle JB. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension. Drugs of today (Barcelona, Spain : 1998). 2019 Sep:55(9):563-574. doi: 10.1358/dot.2019.55.9.3039670. Epub
[PubMed PMID: 31584573]
[4]
Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Experimental eye research. 1998 Aug:67(2):179-91
[PubMed PMID: 9733584]
[5]
Lindsey JD, Gaton DD, Sagara T, Polansky JR, Kaufman PL, Weinreb RN. Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment. Investigative ophthalmology & visual science. 2001 Jul:42(8):1781-6
[PubMed PMID: 11431442]
[6]
Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Investigative ophthalmology & visual science. 1977 Dec:16(12):1125-34
[PubMed PMID: 924742]
[7]
Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Current eye research. 1998 Jun:17(6):567-72
[PubMed PMID: 9663846]
[8]
Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec:102(12):1743-52
[PubMed PMID: 9098273]
[9]
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016 Jan:123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31
[PubMed PMID: 26526633]
Level 2 (mid-level) evidence
[10]
Rácz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Archives of ophthalmology (Chicago, Ill. : 1960). 1996 Mar:114(3):268-73
[PubMed PMID: 8600885]
[11]
Razeghinejad MR. Glaucoma medications in pregnancy. Oman journal of ophthalmology. 2018 Sep-Dec:11(3):195-199. doi: 10.4103/ojo.OJO_212_2017. Epub
[PubMed PMID: 30505107]
[12]
Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM, American Glaucoma Society and the Canadian Glaucoma Society. A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma. Ophthalmology. Glaucoma. 2020 Mar-Apr:3(2):79-89. doi: 10.1016/j.ogla.2019.12.004. Epub
[PubMed PMID: 32672600]
[14]
Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Advances in therapy. 2008 Aug:25(8):743-51. doi: 10.1007/s12325-008-0078-y. Epub
[PubMed PMID: 18670744]
Level 3 (low-level) evidence
[15]
Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Japanese journal of ophthalmology. 2004 Nov-Dec:48(6):602-12
[PubMed PMID: 15592791]
[16]
Holló G, Aung T, Cantor LB, Aihara M. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management. Survey of ophthalmology. 2020 Sep-Oct:65(5):496-512. doi: 10.1016/j.survophthal.2020.02.004. Epub 2020 Feb 22
[PubMed PMID: 32092363]
Level 3 (low-level) evidence
[17]
Villegas VM, Díaz L, Izquierdo NJ. Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report. Puerto Rico health sciences journal. 2008 Dec:27(4):348-9
[PubMed PMID: 19069363]
Level 3 (low-level) evidence
[18]
Tokuda N, Kitaoka Y, Matsuzawa A, Tsukamoto A, Sase K, Sakae S, Takagi H. Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost. Journal of ophthalmology. 2017:2017():3540749. doi: 10.1155/2017/3540749. Epub 2017 Aug 2
[PubMed PMID: 28831305]
[19]
Lee JH, Kim TH, Kim SC. Allergic contact dermatitis caused by topical eye drops containing latanoprost. Annals of dermatology. 2014 Apr:26(2):269-70. doi: 10.5021/ad.2014.26.2.269. Epub 2014 Apr 30
[PubMed PMID: 24882991]
[20]
Bitner DP, Freedman SF. Long-term home monitoring of intraocular pressure in pediatric glaucoma. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2016 Dec:20(6):515-518. doi: 10.1016/j.jaapos.2016.08.003. Epub 2016 Oct 1
[PubMed PMID: 27702611]
[21]
Tressler CS, Wiseman RL, Dombi TM, Jessen B, Huang K, Kwok KK, Wirostko BM. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. The British journal of ophthalmology. 2011 Nov:95(11):1490-5. doi: 10.1136/bjo.2010.193987. Epub 2011 Apr 21
[PubMed PMID: 21515566]
[22]
Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. American journal of ophthalmology. 2003 May:135(5):688-703
[PubMed PMID: 12719078]
Level 2 (mid-level) evidence